腹腔镜与开腹肝切除治疗肝硬化肝细胞癌的Meta分析
该Meta分析纳入11项研究共1618例患者(腹腔镜组690例 vs 开腹组928例),比较腹腔镜与开腹肝切除治疗肝硬化合并肝细胞癌的疗效。结果显示腹腔镜组死亡风险降低(两阶段合并HR 0.84,95%CI 0.74-0.96,P=0.01),且出血量更少、总体及严重并发症更少、住院时间更短。结论认为腹腔镜切除与改善生存和围术期结局相关。
要点
- 腹腔镜组死亡风险显著低于开腹组(合并HR 0.84,95%CI 0.74-0.96,P=0.01)。
- 腹腔镜组出血量更少(MD -99 ml,95%CI -182至-16 ml),并发症更少。
- 腹腔镜组住院时间更短(MD -3.22天,95%CI -4.38至-2.06天)。
核心结论
- 腹腔镜切除肝硬化合并肝细胞癌与改善生存和围术期结局相关。
研究设计与样本
- 系统检索PubMed、EMBASE、Scopus和Web of Science数据库,纳入报告肝硬化合并肝细胞癌腹腔镜与开腹肝切除结局的随机对照试验和倾向性评分匹配研究。
- 共纳入11项研究,1618例患者(腹腔镜组690例 vs 开腹组928例)。
- 主要结局为总生存,采用一阶段(个体 participant 数据Meta分析)和两阶段(聚合数据Meta分析)方法分析。
主要发现
- 一阶段Meta分析显示腹腔镜组死亡风险降低约18.7%(随机效应HR 0.81,95%CI 0.68-0.96,P=0.018)。
- 两阶段Meta分析显示腹腔镜组合并HR为0.84(95%CI 0.74-0.96,P=0.01),相当于死亡风险降低16-26%。
- 腹腔镜组出血量更少(MD -99 ml,95%CI -182至-16 ml)。
- 腹腔镜组总体并发症(OR 0.49,95%CI 0.37-0.66)和严重并发症(OR 0.45,95%CI 0.26-0.79)更少。
- 腹腔镜组住院时间更短(MD -3.22天,95%CI -4.38至-2.06天)。
临床怎么用
- 作者结论认为腹腔镜切除肝硬化合并肝细胞癌与改善生存和围术期结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The exact role of laparoscopic liver resection (LLR) in patients with hepatocellular carcinoma (HCC) and underlying liver cirrhosis (LC) is not well defined. In this meta-analysis, both long- and short-term outcomes following LLR versus open liver resection (OLR) were analysed. METHODS: PubMed, EMBASE, Scopus and Web of Science databases were searched systematically for randomised controlled trials (RCTs) and propensity-score matched (PSM) studies reporting outcomes of LLR versus OLR of HCC in patients with cirrhosis. Primary outcome was overall survival (OS). This was analysed using one-stage (individual participant data meta-analysis) and two-stage (aggregate data meta-analysis) approaches. Secondary outcomes were operation duration, blood loss, blood transfusion, Pringle manoeuvre utilization, overall and major complications, length of hospital stay (LOHS), 90-day mortality and R0 resection rates. RESULTS: Eleven studies comprising 1618 patients (690 LLR versus 928 OLR) were included for analysis. In the one-stage meta-analysis, an approximately 18.7 per cent lower hazard rate (HR) of death in the LLR group (random effects: HR 0.81, 95 per cent confidence interval [C.I.] 0.68 to 0.96; P = 0.018) was observed. Two-stage meta-analysis resulted in a pooled HR of 0.84 (95 per cent C.I. 0.74 to 0.96; P = 0.01) in the overall LLR cohort. This indicated a 16-26 per cent reduction in the HR of death for patients with HCC and cirrhosis who underwent LLR. For secondary outcomes, LLR was associated with less blood loss (mean difference [MD] -99 ml, 95 per cent C.I. -182 to -16 ml), reduced overall complications (odds ratio 0.49, 95 per cent C.I. 0.37 to 0.66) and major complications (odds ratio 0.45, 95 per cent C.I. 0.26 to 0.79), and shorter LOHS (MD -3.22 days, 95 per cent C.I. -4.38 to -2.06 days). CONCLUSION: Laparoscopic resection of HCC in patients with cirrhosis is associated with improved survival and perioperative outcomes.
引用
- Kabir T, Tan ZZ, Syn NL, et al. Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis: meta-analysis. Br J Surg. 2021. PMID: 34757385. doi:10.1093/bjs/znab376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。